Vivian M Abascal, MD
img_Vivian M Abascal
ASSOCIATE CLINICAL PROFESSOR | Medicine, Cardiology
Are you a patient?
Specialties
Cardiovascular Disease (Heart Disease), Cardiology (Heart)

MD, Universidad Central de Venezuela

Internship, Internal Medicine, UMass Memorial Medical Center-University Campus

Residency, Cardiology, Boston University Medical Center

Certifications

American Board of Internal Medicine
Publications

Selected Publications

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes. Maeve Soto Pérez, Jorge Rodríguez-Capitán, Juan Antonio Requena-Ibáñez, Carlos G. Santos-Gallego, M. Urooj Zafar, Ginés Escolar, Donna Mancini, Sumeet Mitter, David Lam, Johanna P. Contreras, Icilma Fergus, Farah Atallah-Lajam, Vivian Abascal, Anu Lala, Pedro Moreno, Noah Moss, Stamatios Lerakis, Javier Sanz, Valentin Fuster, Juan José Badimon. Cardiovascular Drugs and Therapy

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. Carlos G. Santos-Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez, Anderly Rodriguez-Cordero, M. Urooj Zafar, Icilma Fergus, Farah Atallah-Lajam, Johanna P. Contreras, Cathleen Varley, Pedro R. Moreno, Vivian M. Abascal, Anuradha Lala, Ronald Tamler, Javier Sanz, Valentin Fuster, Juan J. Badimon. Journal of the American College of Cardiology

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?. Carlos G. Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, Sean P. Pinney, Johanna P. Contreras, Icilma Fergus, Vivian Abascal, Pedro Moreno, Farah Atallah-Lajam, Ronald Tamler, Anu Lala, Javier Sanz, Valentin Fuster, Juan Jose Badimon. Cardiovascular Drugs and Therapy

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Abascal has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.